Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction.
Anaphylactic shock and chemical stimulation of isolated lungs are followed by the release of pharmacologically active lipids, such as the eicosanoids. The metabolic modifications that lungs undergo during stimulation, and the effects of the various chemical agents, indicate that other mediators should be released as well. The effects of one of these potential mediators, "platelet-activating factor", are reviewed, particularly with respect to the inhibition of its bronchopulmonary and platelet effects.
D000707:Anaphylaxis / Q000378:metabolism; D000818:Animals; D001792:Blood Platelets / Q000378:metabolism; D001980:Bronchi / Q000503:physiopathology; D006168:Guinea Pigs; D006632:Histamine / Q000378:metabolism; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D008168:Lung / Q000378:metabolism*; D010743:Phospholipids / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000096:biosynthesis; D010974:Platelet Aggregation; D011453:Prostaglandins / Q000378:metabolism; D011817:Rabbits; D013189:SRS-A / Q000378:metabolism; D013931:Thromboxanes / Q000378:metabolism
D010743:Phospholipids; D010972:Platelet Activating Factor; D011453:Prostaglandins; D013189:SRS-A; D013931:Thromboxanes; D006632:Histamine